Streetbeat News

Equity Actions

DIS

Disney has disclosed a $1.5 billion stake in Epic Games, revealing approximately 8% ownership in a recent regulatory filing.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 1:52 pm

MU

Micron Technology shares are trading higher after the company announced the resumption of its stock repurchase program.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 1:29 pm

HEPA

Hepion Pharmaceuticals announced that Interim CEO and CFO John Cavan has departed. Executive Chairman John Brancaccio has been appointed as the new Interim CEO and CFO.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 1:09 pm

XPON

Expion360 has announced the pricing of a $10 million underwritten public offering.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:51 pm

MU

Micron Technology has resumed its stock repurchase program, initially authorized in 2018 and suspended in December 2022, to offset dilution from employee stock purchase programs. The company remains committed to strengthening its balance sheet and maintaining its investment-grade credit rating.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:47 pm

CHRO

Chromocell Therapeutics has announced a $250,000 stock repurchase plan, which represents 23% of its non-affiliate float. The Board of Directors has authorized the plan with the flexibility to modify or terminate it.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:45 pm

INDP

Indaptus Therapeutics has entered into securities purchase agreements with investors for the issuance and sale of 1,643,837 common shares, raising $3.0 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:22 am

BENF

Beneficient announced a private placement of $4.0 million in convertible debentures and warrants priced at-the-market.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:20 am

CYCN

Cyclerion Therapeutics announced the promotion of Regina Graul, Ph.D., to Chief Executive Officer, President, and Member of the Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:16 am

CRL

Charles River Laboratories' Board has approved a new stock repurchase authorization of $1 billion, indicating confidence in the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:01 am